首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Mitotically active cellular fibroma of ovary should be differentiated from fibrosarcoma: a case report and review of literature
【2h】

Mitotically active cellular fibroma of ovary should be differentiated from fibrosarcoma: a case report and review of literature

机译:卵巢丝裂活跃性细胞纤维瘤应与纤维肉瘤区分开来:一例病例报告并文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The clinicopathologic characteristic of mitotically active cellular fibroma is significantly different from the malignant behavior of ovarian fibrosarcoma. Therefore, it’s very important to differentiate mitotically active cellular fibroma from ovarian fibrosarcoma. We report a case in which a 39-year-old woman was found with an ovarian tumor measuring 105 × 71 × 47 mm. The tumor ruptured and adhered to the peritoneum. Microscopic examination showed densely cellular spindle-shaped tumor cells. The cellular atypia was mild. The Ki-67 proliferation index was approximately 10%. The patient remained free of tumor for more than 66 months without any adjuvant chemotherapy after operation. After reviewing the literature, we diagnosed this case as mitotically active cellular fibroma rather than ovarian fibrosarcoma. It is very important to differentiate these two tumors because of the marked differences in treatment modalities and prognosis between them. The ovarian fibrous tumors with mitotic figures ≥ 4 per 10 high-power fields but no severe nuclear atypia should be mostly diagnosed as mitotically active cellular fibroma of ovary. The correct diagnosis is the key to avoid excessive treatments.
机译:有丝分裂活动性细胞纤维瘤的临床病理特征与卵巢纤维肉瘤的恶性行为明显不同。因此,区分有丝分裂活跃的细胞纤维瘤和卵巢纤维肉瘤非常重要。我们报告了一个病例,其中发现一名39岁的女性患有卵巢肿瘤,尺寸为105×71×47 mm。肿瘤破裂并粘附在腹膜上。镜检可见致密的纺锤形肿瘤细胞。细胞非典型性轻度。 Ki-67增殖指数约为10%。病人在手术后没有任何辅助化疗的情况下保持肿瘤超过66个月。在回顾文献之后,我们将这种情况诊断为有丝分裂活跃的细胞纤维瘤,而不是卵巢纤维肉瘤。区分这两种肿瘤非常重要,因为它们之间的治疗方式和预后存在明显差异。每10个高倍视野中有丝分裂指数≥4的卵巢纤维瘤,但无严重的核异型,应主要诊断为卵巢有丝分裂活跃的细胞纤维瘤。正确的诊断是避免过度治疗的关键。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号